Editas Medicine Financial Statements (EDIT)
|
|
|
|
Report date
|
|
|
26.02.2020 |
26.02.2021 |
24.02.2022 |
22.02.2023 |
28.02.2024 |
|
04.11.2024 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
20.5 |
90.7 |
25.5 |
19.7 |
78.1 |
|
61.8 |
|
Operating Income, bln rub |
|
|
-140.9 |
-134.8 |
-193.1 |
-226.0 |
-169.2 |
|
-228.5 |
|
EBITDA, bln rub |
? |
|
-138.1 |
-130.9 |
-188.1 |
-219.6 |
-163.1 |
|
-219.1 |
|
Net profit, bln rub |
? |
|
-123.5 |
-109.4 |
-185.1 |
-204.4 |
-153.2 |
|
-210.6 |
|
|
OCF, bln rub |
? |
|
-40.7 |
-179.8 |
-163.8 |
-177.3 |
-132.2 |
|
-181.8 |
|
CAPEX, bln rub |
? |
|
6.17 |
7.16 |
7.98 |
4.12 |
4.72 |
|
9.59 |
|
FCF, bln rub |
? |
|
-46.8 |
-187.0 |
-171.8 |
-181.5 |
-136.9 |
|
-191.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0 |
|
|
OPEX, bln rub |
|
|
161.5 |
225.6 |
218.7 |
245.7 |
247.3 |
|
286.0 |
|
Cost of production, bln rub |
|
|
96.9 |
158.0 |
5.05 |
6.34 |
177.7 |
|
5.89 |
|
R&D, bln rub |
|
|
96.9 |
158.0 |
142.5 |
175.0 |
177.7 |
|
168.3 |
|
Interest expenses, bln rub |
|
|
0.000 |
0.000 |
0.000 |
4.23 |
0.000 |
|
3.47 |
|
|
Assets, bln rub |
|
|
508.9 |
572.6 |
677.5 |
514.3 |
499.2 |
|
327.6 |
|
Net Assets, bln rub |
? |
|
262.4 |
393.6 |
553.6 |
360.7 |
349.1 |
|
175.6 |
|
Debt, bln rub |
|
|
29.1 |
26.1 |
26.4 |
43.9 |
36.5 |
|
38.5 |
|
Cash, bln rub |
|
|
457.1 |
511.8 |
619.9 |
437.4 |
323.1 |
|
265.1 |
|
Net debt, bln rub |
|
|
-428.1 |
-485.6 |
-593.5 |
-393.4 |
-286.6 |
|
-226.6 |
|
|
Ordinary share price, rub |
|
|
29.6 |
70.1 |
26.6 |
8.87 |
10.1 |
|
7.04 |
|
Number of ordinary shares, mln |
|
|
50.0 |
58.6 |
67.6 |
68.7 |
76.0 |
|
82.5 |
|
|
Market cap, bln rub |
|
|
1 480 |
4 109 |
1 795 |
609 |
770 |
|
581 |
|
EV, bln rub |
? |
|
1 052 |
3 623 |
1 202 |
216 |
483 |
|
354 |
|
Book value, bln rub |
|
|
262 |
394 |
554 |
361 |
349 |
|
176 |
|
|
EPS, rub |
? |
|
-2.47 |
-1.87 |
-2.74 |
-2.98 |
-2.02 |
|
-2.55 |
|
FCF/share, rub |
|
|
-0.94 |
-3.19 |
-2.54 |
-2.64 |
-1.80 |
|
-2.32 |
|
BV/share, rub |
|
|
5.25 |
6.72 |
8.19 |
5.25 |
4.60 |
|
2.13 |
|
|
EBITDA margin, % |
? |
|
-672.6% |
-144.3% |
-736.3% |
-1 114% |
-208.8% |
|
-354.8% |
|
Net margin, % |
? |
|
-601.4% |
-120.6% |
-724.7% |
-1 037% |
-196.1% |
|
-341.0% |
|
FCF yield, % |
? |
|
-3.16% |
-4.55% |
-9.57% |
-29.8% |
-17.8% |
|
-33.0% |
|
ROE, % |
? |
|
-47.0% |
-27.8% |
-33.4% |
-56.7% |
-43.9% |
|
-119.9% |
|
ROA, % |
? |
|
-24.3% |
-19.1% |
-27.3% |
-39.7% |
-30.7% |
|
-64.3% |
|
|
P/E |
? |
|
-12.0 |
-37.6 |
-9.70 |
-2.98 |
-5.02 |
|
-2.76 |
|
P/FCF |
|
|
-31.6 |
-22.0 |
-10.5 |
-3.36 |
-5.62 |
|
-3.03 |
|
P/S |
? |
|
72.1 |
45.3 |
70.3 |
30.9 |
9.85 |
|
9.40 |
|
P/BV |
? |
|
5.64 |
10.4 |
3.24 |
1.69 |
2.20 |
|
3.31 |
|
EV/EBITDA |
? |
|
-7.62 |
-27.7 |
-6.39 |
-0.98 |
-2.96 |
|
-1.62 |
|
Debt/EBITDA |
|
|
3.10 |
3.71 |
3.16 |
1.79 |
1.76 |
|
1.03 |
|
|
R&D/CAPEX, % |
|
|
1 571% |
2 206% |
1 786% |
4 249% |
3 765% |
|
1 755% |
|
|
CAPEX/Revenue, % |
|
|
30.0% |
7.89% |
31.2% |
20.9% |
6.04% |
|
15.5% |
|
| Editas Medicine shareholders |
